The estimated Net Worth of Einat Brill Almon is at least $839 mil dollars as of 2 May 2012. Dr Almon owns over 166,848 units of Protalix BioTherapeutics stock worth over $173,522 and over the last 17 years he sold PLX stock worth over $0. In addition, he makes $665,703 as Sr. VP & Chief Devel. Officer at Protalix BioTherapeutics.
Sign up
Dr Almon PLX stock SEC Form 4 insiders trading
Dr has made over 7 trades of the Protalix BioTherapeutics stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 166,848 units of PLX stock worth $245,267 on 2 May 2012.
The largest trade he's ever made was exercising 166,848 units of Protalix BioTherapeutics stock on 2 May 2012 worth over $245,267. On average, Dr trades about 35,580 units every 97 days since 2008. As of 2 May 2012 he still owns at least 166,848 units of Protalix BioTherapeutics stock.
You can see the complete history of Dr Almon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Einat Brill-Almon biography
Dr. Einat Brill-Almon is the Sr. VP & Chief Devel. Officer at Protalix BioTherapeutics.
What is the salary of Dr Almon?
As the Sr. VP & Chief Devel. Officer of Protalix BioTherapeutics, the total compensation of Dr Almon at Protalix BioTherapeutics is $665,703. There are no executives at Protalix BioTherapeutics getting paid more.
How old is Dr Almon?
Dr Almon is 61, he's been the Sr. VP & Chief Devel. Officer of Protalix BioTherapeutics since . There are 6 older and 7 younger executives at Protalix BioTherapeutics. The oldest executive at Protalix BioTherapeutics Inc. is Aharon Schwartz, 75, who is the Independent Director.
What's Dr Almon's mailing address?
Einat's mailing address filed with the SEC is 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL, L3, 2161401.
Insiders trading at Protalix BioTherapeutics
Over the last 18 years, insiders at Protalix BioTherapeutics have traded over $46,705,936 worth of Protalix BioTherapeutics stock and bought 4,403,619 units worth $4,673,005 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Capital Management Lp Camber y Ltd Bio Cell. On average, Protalix BioTherapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $404,231. The most recent stock trade was executed by Dror Bashan on 19 October 2023, trading 64,516 units of PLX stock currently worth $90,322.
What does Protalix BioTherapeutics do?
protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase
What does Protalix BioTherapeutics's logo look like?
Complete history of Dr Almon stock trades at Protalix BioTherapeutics
Protalix BioTherapeutics executives and stock owners
Protalix BioTherapeutics executives and other stock owners filed with the SEC include:
-
Dr. Einat Brill-Almon,
Sr. VP & Chief Devel. Officer -
Dror Bashan,
Pres, CEO & Director -
Einat Almon,
Senior Vice President, Chief Development Officer -
Eyal Rubin M.B.A.,
Sr. VP, CFO, Treasurer & Corp. Sec. -
Marcy Nanus,
Investor Contact -
Aharon Schwartz,
Independent Director -
David Granot,
Independent Director -
Amos Bar-Shalev,
Independent Director -
Gwen Melincoff,
Director -
Pol Boudes,
Director -
Yael Hayon,
Vice President - Research & Development -
Yaron Naos,
Senior Vice President - Operations -
Eyal Rubin,
Chief Financial Officer, Senior Vice President -
Dror Bashan,
President, Chief Executive Officer, Director -
Zeev Bronfeld,
Chairman of the Board -
Dafna Shelly M.Sc., MBA,
VP of HR -
Yaron Naos,
Sr. VP of Operations -
Capital Management Lp Camber,
10% owner -
Yoseph Shaaltiel,
Executive VP, R&D -
Tzvi Palash,
Chief Operating Officer -
Moshe Manor,
President & CEO -
Yossi Maimon,
VP, Chief Financial Officer -
Sandra Leigh Lauterbach,
VP, Sales & Commercial Affairs -
David Aviezer,
President & CEO -
Ltd Bio Cell,
10% owner -
Shlomo Yanai,
Director -
Alfred Akirov,
Director -
Eli Hurvitz,
Director -
Roger D. Kornberg,
Director -
Phillip Md Et Al Frost Gamm...,
-
Iftah Katz,
VP of Operations -
Pharma Technologies Ltd.Ore...,
-
Eliot Forster,
Director -
Zvi Shmuel Ben,